drugset / Trial / NCT04224415
Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC
NaSingle-groupOpen-labelTreatment
Summary
The aim of the trial is to study the efficacy and safety of Cetuximab re-challenge for Chinese Patients with RAS/BRAF wild-type Metastatic Colorectal Cancer.
Timeline
- Start
- 2020-01-31
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Background | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |